Turnover: 28.541 billion EUR (2022)
Country: United States
An international company serving patients and healthcare professionals
Lilly has been present in France since 1962, covering the entire drug chain, from research to production and marketing.
The Group's largest production site for injectable treatments is located in Fegersheim, Alsace (France).
News
Eli Lilly has become the world's largest pharmaceutical company 08/06/2023
- Eli Lilly market capitalization: $408 billion
- Obesity market estimate for 2030: $100 billion.
- Obesity market estimate for 2022: $4 billion.
- Number of people suffering from Alzheimer's disease worldwide: 55 million.
- Number of Alzheimer's sufferers in Europe: 10 million.
- Estimated Alzheimer's disease market in 2020: 30 billion euros.
Financial Data
DUNS: 609849153
Legal Name: LILLY FRANCE
Address: 24 BD VITAL BOUHOT CS 50004, 92200 NEUILLY-SUR-SEINE
Number of employees: Entre 1 000 et 1 999 salariés (2020)
Capital: 375 713 701 EUR
Financial Data:
| Year | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|
| Turnover | 974 857 331 | 837 314 025 | 782 045 403 | 3 139 619 284 | 3 101 346 326 | 2 812 180 672 | 2 721 970 411 |
| Gross margin (€) | 458 736 661 | 433 517 290 | 451 158 853 | 465 529 339 | 425 748 440 | 490 816 410 | 446 714 409 |
| EBITDA (€) | 117 501 846 | 110 848 510 | 106 900 071 | 90 531 219 | 49 060 462 | 233 856 635 | 92 769 536 |
| Operating profit (€) | 63 281 785 | 56 205 633 | 54 480 530 | 37 258 667 | 777 664 | -214 770 053 | 36 387 334 |
| Net profit (€) | 47 484 018 | 35 489 962 | 45 809 155 | 81 786 700 | 35 792 336 | 36 741 323 | 24 387 865 |
| Turnover growth rate (%) | 16,4 | 7,1 | -75,1 | 1,2 | 10,3 | 3,3 | - |
| Ebitda margin rate (%) | 12,1 | 13,2 | 13,7 | 2,9 | 1,6 | 8,3 | 3,4 |
| Operating margin rate (%) | 6,5 | 6,7 | 7 | 1,2 | - | -7,6 | 1,3 |
| Working Capital (turnover days) | 63,7 | 94,9 | 110,1 | 32,9 | 168,8 | 152,2 | 144,8 |
| Working Capital requirements (turnover days) | 33,3 | 53,4 | 58,5 | 16,3 | 180,8 | 162,6 | 154,6 |
| Net margin (%) | 4,9 | 4,2 | 5,9 | 2,6 | 1,2 | 1,3 | 0,9 |
| Added value / Turnover (%) | 32,7 | 37,7 | 40,7 | 9,5 | 8 | 30,2 | 11 |
| Wages and social charges (€) | 173 116 738 | 176 633 735 | 184 780 608 | 180 032 248 | 178 084 225 | 172 810 940 | 183 489 133 |
| Salaries / Turnover (%) | 17,8 | 21,1 | 23,6 | 5,7 | 5,7 | 6,1 | 6,7 |
Company Managers:
| Position | First Name | Last Name | Age | |
|---|---|---|---|---|
| Président | Marcel | LECHANTEUR | 60 | |
| Directeur général | Gilles | HUBERT | 51 |
Studies mentioning this company
The Insulin Pump Market - France
Other companies mentioned:
- Medtronic
- Cellnovo
- Roche Diabetes Care (Roche Groupe)
- Insulet
- Ypsomed Group
- ISIS diabète (Isis Médical)
- Physidia
- Nova Medical Center
- Medtrum
- Apex Wellell
- Open APS
- Eli Lilly
- TreeFrog Therapeutics
- Boydsense
> Besoin de plus d'information sur cette entreprise (SWOT, PESTEL, son marché) ? Demandez à SectorGPT (gratuit)
Sector-GPT est la première IA dédiée aux informations sectorielles.